ArticleAnnals of surgical oncology2026
Prognostic Benefit of Sequential Locoregional Interventions During First-Line Systemic Therapy for Hepatocellular Carcinoma: Insights from Interaction Analysis of Lenvatinib and Atezolizumab/Bevacizumab.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAchieving conversion therapy for advanced hepatocellular carcinoma (HCC) is a promising strategy. However, it remains unclear whether the prognostic impact of these interventions differs depending on the first-line systemic regimen. PATIENTS AND
methodsWe retrospectively analyzed 189 patients with advanced HCC who received first-line systemic therapy. Independent prognostic factors for overall survival (OS) were identified using Firth's penalized Cox proportional hazards models. Interaction analysis was performed to assess whether the benefit of interventions varied by regimen.
resultsInterventions were significantly associated with improved OS in the entire cohort. Notably, achieving R0 status provided the most substantial survival benefit, with no significant interaction between regimens (P = 0.425; hazard ratio [HR] 0.074 for lenvatinib, HR 0.406 for atezolizumab/bevacizumab). Transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) was also associated with improved OS, showing a more pronounced benefit in the lenvatinib group than in the atezolizumab/bevacizumab group (P = 0.105; HR 0.350 versus 0.726).
conclusionsAchieving R0 status through conversion therapy is a universal goal for maximizing OS, regardless of the initial systemic regimen. Lenvatinib may offer a more favorable platform for sequential TACE/HAIC to prolong overall survival compared to atezolizumab/bevacizumab.
Indexed as
Identifiers
42448977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.